tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

ESALY

Eisai, Biogen say lecanemab received Priority Review status in Japan
The FlyEisai, Biogen say lecanemab received Priority Review status in Japan
2y ago
BIIB
Eisai, Biogen: EMA accepts MAA for lecanemab for early Alzheimer’s disease
PremiumThe Fly
Eisai, Biogen: EMA accepts MAA for lecanemab for early Alzheimer’s disease
2y ago
BIIB
Catalyst Pharmaceuticals completes acquisition of U.S. rights to FYCOMPA CII
PremiumThe Fly
Catalyst Pharmaceuticals completes acquisition of U.S. rights to FYCOMPA CII
2y ago
CPRX
Donanemab CRL a ‘positive headline’ for Biogen’s Leqembi, says William Blair
PremiumThe Fly
Donanemab CRL a ‘positive headline’ for Biogen’s Leqembi, says William Blair
2y ago
LLY
BIIB
Eisai submits marketing authorization application for lecanemab in Japan
PremiumThe Fly
Eisai submits marketing authorization application for lecanemab in Japan
2y ago
BIIB
Eisai submits MAA for lecanemab to EMA
PremiumThe FlyEisai submits MAA for lecanemab to EMA
2y ago
BIIB
Eisai submits Leqembi sBLA to FDA
Premium
The Fly
Eisai submits Leqembi sBLA to FDA
2y ago
ESALY
CMS says Biogen approval falls under existing national coverage determination
Premium
The Fly
CMS says Biogen approval falls under existing national coverage determination
2y ago
BIIB
Eisai announces Leqembi U.S. launch pricing at $26,500 per year
PremiumThe Fly
Eisai announces Leqembi U.S. launch pricing at $26,500 per year
2y ago
BIIB
Biogen, Eisai announce FDA approves Leqembi to treat Alzheimer’s disease
PremiumThe Fly
Biogen, Eisai announce FDA approves Leqembi to treat Alzheimer’s disease
2y ago
BIIB
FDA grants accelerated approval for Biogen and Eisai Alzheimer’s drug
PremiumThe Fly
FDA grants accelerated approval for Biogen and Eisai Alzheimer’s drug
2y ago
BIIB
Needham health/pharmaceuticals analysts hold analyst/industry conference call
PremiumThe Fly
Needham health/pharmaceuticals analysts hold analyst/industry conference call
2y ago
BIIB
Needham health/pharmaceuticals analysts hold analyst/industry conference call
PremiumThe FlyNeedham health/pharmaceuticals analysts hold analyst/industry conference call
2y ago
BIIB
Needham health/pharmaceuticals analysts hold analyst/industry conference call
Premium
The Fly
Needham health/pharmaceuticals analysts hold analyst/industry conference call
2y ago
BIIB
Biogen’s Alzheimer’s Drug Could be Expensive
Premium
Market News
Biogen’s Alzheimer’s Drug Could be Expensive
2y ago
BIIB
Third trial death tied to Biogen and Eisai Alzheimer’s drug, Science reports
PremiumThe Fly
Third trial death tied to Biogen and Eisai Alzheimer’s drug, Science reports
2y ago
BIIB
Eisai initiates BLA submission of data for lecanemab in China
PremiumThe Fly
Eisai initiates BLA submission of data for lecanemab in China
2y ago
BIIB
Frontage partners with Eisai, Biogen to complete the Clarity AD study
PremiumThe Fly
Frontage partners with Eisai, Biogen to complete the Clarity AD study
2y ago
BIIB
Anavex price target raised to $80 from $40 at JonesTrading
PremiumThe Fly
Anavex price target raised to $80 from $40 at JonesTrading
2y ago
AVXL
BIIB
Mizuho healthcare analysts to hold an analyst/industry conference call
PremiumThe FlyMizuho healthcare analysts to hold an analyst/industry conference call
2y ago
BIIB
Mizuho healthcare analysts to hold an analyst/industry conference call
Premium
The Fly
Mizuho healthcare analysts to hold an analyst/industry conference call
2y ago
BIIB
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
Premium
The Fly
Mizuho says Biogen not mentioned in 90 minute lecanemab presentation
2y ago
BIIB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >